News

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor ...
The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.
Jazz Pharmaceuticals (JAZZ) stock gains as its lung cancer therapy Zepzelca, in combination with Roche's Tecentriq, receives FDA priority review. Read more here.
Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...
Lung cancer remains the leading cause of cancer mortality worldwide. Immunotherapy has recently emerged as a promising therapeutic strategy both for ...
Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the ...
Lung cancer is the leading cause of cancer-related mortality globally. Although low-dose computed tomography (LDCT) has shown ...
Researchers in China say the bacteria in your gut—and beyond—may play a role in your chance of developing one of the leading ...
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...
NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with ...